Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cycloserine/lurasidone - NRx Pharmaceuticals

Next Previous
Drug Profile

Cycloserine/lurasidone - NRx Pharmaceuticals

Alternative Names: Cyclurad; D-cycloserine/lurasidone.; Lurasidone/cycloserine; NRX-101

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroRX
  • Developer NeuroRX; NRx Pharmaceuticals
  • Class Analgesics; Anti-infectives; Antidepressants; Antituberculars; Anxiolytics; Behavioural disorder therapies; Isoindoles; Isoxazoles; Piperazines; Small molecules; Thiazoles; Urinary anti-infective agents
  • Mechanism of Action 5-HT2C serotonin receptor antagonists; Cell wall inhibitors; Dopamine D2 receptor antagonists; Glycine gated NMDA receptor agonists; Serotonin 5-HT2A receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Urinary tract infections

Highest Development Phases

  • Phase III Bipolar depression
  • Phase II/III Suicidal ideation
  • Phase II Pain
  • Preclinical Post-traumatic stress disorders; Urinary tract infections

Most Recent Events

  • 03 Dec 2025 NRx Pharmaceuticals amends IND application for cycloserine/lurasidone with transcranial magnetic stimulation for Depression
  • 17 Nov 2025 NRx Pharmaceuticals plans a confirmatory phase III trial for Bipolar disorders in early 2026
  • 12 Nov 2025 NRx Pharmaceuticals plans a phase II/III trial for Major depressive disorder (Treatment-experienced) in USA (PO) in March 2026 (NCT07227103)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top